We focus on new immunotherapy
That can harness natural immune system to fight cancer.
With a potential for producing long-term remission and cures.
And on clinical trials to help canine patients
The trials start as pilot studies with a small number of patients. If the results are promising, a larger pivotal study is launched to gather more data so the therapy can be approved for wide use.
(The studies we support NEVER involve laboratory dogs)
The following studies are supported by your generous donations and are creating new therapies that are:
2. More Effective
Prof. Mamula and Ranger who is fighting osteosarcoma metastasis with the help of Yale vaccine
Therapeutic Vaccine for Osteosarcoma and other EGFR/HER2 over-expressing tumors
Tumors that over-express EGFR/HER2 antigens are often very aggressive, and include osteosarcoma, hemangiosarcoma, mammary tumors, and bladder cancer. In a study led by Professor Mark Mamula at Yale Medical School, a new therapeutic vaccine is being evaluated to extend survival times of cancer patients. The team's initial findings, shared at ACVIM 2021, shows that the vaccine helps to extend median survival times compared to standard-of-care for canine patients.
What is most exciting is that several dogs with pulmonary metastasis experienced tumor regression with the help of the vaccine. A new larger study will be launched to evaluate the efficacy of the vaccine with more patients. Read more here.
Multi-Antigen Vaccine Targeting Cancer Stem Cells
A group at University of Washington Cancer Vaccine Institute is evaluating the safety and efficacy of vaccines that simultaneously target multiple proteins associated with cancer cells, including cancer stem cells.
By targeting cancer stem cells, it may be possible to reduce the risk of metastasis following surgery or other conventional therapy. The team is planning to launch a clinical study and enroll canine cancer patients soon.
Conventional cancer treatments are unable to target cancer stem cells due to their highly resistant nature, leading to metastasis and tumor recurrence.
Non-Specific Immune Stimulating Therapy
Certain bacteria can stimulate the immune system to help fight cancer.
A study is underway to evaluate the efficacy of Immunocidin - mycobacterial cell wall fraction (MCWF) - in fighting cancerous growth.
This approach is similar to the original Coley's Toxin invented over 120 years ago, but utilizes nonpathogeneic bacteria.
MCWE was originally approved for use to treat mammary tumors but the new pilot study is enrolling patients with osteosarcoma, transitional cell carcinoma and other solid tumors.
After 1-year old Rigsby was diagnosed with fibrosarcoma, his vet began treating him with Immunocidin as part of a new study.
More accessible and affordable cancer therapy
Today, cancer treatments can be very expensive and there may not even be a local veterinarian who can administer the treatment.
What if there is an effective but inexpensive and simple-to-administer solution that could be provided by a local veterinarian?
This is the challenge that Professor Rachel Allavena at Queensland University is passionate about. Her team is evaluating a new immunotherapy treatment that aims to be both inexpensive and accessible.
Prof Ravenna is leading an effort to create effective cancer therapies that are affordable and accessible to all patients.
Pro-inflammatory Cytokine To Fight Canine Cancers
Cytokines are powerful molecules that are excreted by immune cells to turn up or turn off the immune system. But because of potential toxic side-effects, direct infusion of immune-stimulatory cytokines has rarely been used for cancer therapy. A team of scientists have now figured out a way to use IL-12 therapy in a way to safely and effectively fight cancer. This work, originally launched in Seattle, is now led by a team at Northwestern University.